Since osteoporosis and obesity are two diseases that affect a vast majority of postmenopausal women concomitantly, using a single drug that is Food and Drug Administration (FDA) approved for obesity to prevent and manage both osteoporosis and obesity could improve the quality of life and decrease the complications and medical costs that occur as a result of both diseases
Whats in the plan Built for GLP-1 Success Created specifically with GLP-1 users in mind, this plan supports critical nutrient targetsespecially protein, fiber, and hydrationwhile helping manage common medication-related challenges like appetite changes and digestive shifts
You may be able to see and feel them
In the South, some exceptions are Kentucky, Georgia, and Tennessee, which cover Wegovy for state employees, and Mississippi and North Carolina, which provides coverage in Medicaid
Studies that met the following inclusion criteria were selected: 1) A study population consisting of NAFLD or NASH patients diagnosed with biopsy or other imaging methods, 2) adult participants, 3) GLP-1RA or TZD treatment as intervention group, 4) active or placebo control group, 5) at least 3 months of treatment duration, 6) liver biopsy-based, noninvasive technique-based, biological parameters, or anthropometric parameters as outcomes
